Cencora, Inc. (COR)
(Delayed Data from NYSE)
$236.67 USD
-1.08 (-0.45%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $236.65 -0.02 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.67 USD
-1.08 (-0.45%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $236.65 -0.02 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Stryker (SYK) Completes First Arthroplasty Surgery in Europe
by Zacks Equity Research
Stryker (SYK) completes its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.
DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval
by Zacks Equity Research
DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.
Reasons to Retain Prestige Consumer (PBH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Prestige Consumer (PBH) on increasing gain in market share for its wide array of brands.
CVS Health (CVS) Expands In-Home Diagnostic Care With New Test
by Zacks Equity Research
CVS Health's (CVS) new launch will enable early detection of heart arrhythmia and can help mitigate symptoms and more severe complications.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio
by Zacks Equity Research
Ecolab's (ECL) focus on R&D raises optimism about the stock.
Lantheus' (LNTH) DEFINITY Approved by FDA for Pediatric Use
by Zacks Equity Research
Lantheus' (LNTH) receipt of the expanded indication for DEFINITY is likely to address unmet medical needs of pediatric patients.
BD (BDX) Initiates IDE Study to Aid Treatment of Artery Disease
by Zacks Equity Research
BD (BDX) commences the enrollment of the first patient in the IDE study for the assessment of the company's Vascular Covered Stent for the treatment of Peripheral Arterial Disease.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Philips (PHG), SyntheticMR Unite to Aid Brain Diagnosing Space
by Zacks Equity Research
Philips (PHG) and SyntheticMR collaborate to launch of Smart Quant Neuro 3D, which is likely to boost the brain diagnosing field by providing automatic and precise 3D segmentation of brain tissues.
GE HealthCare's (GEHC) New Launch to Enhance Precision Care
by Zacks Equity Research
GE HealthCare's (GEHC) latest innovations are likely to provide patient-centered care for a broad patient population in a variety of clinical settings.
Beat the Market the Zacks Way: Freshpet, NVIDIA, QuantaSing in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Centene (CNC), Pyx Health Unite to Treat Mental Health Issues
by Zacks Equity Research
Centene (CNC) partners with Pyx Health to address loneliness and mental health issues among the insured.
Philips' (PHG) CT 5300 to Boost Diagnostic Capabilities
by Zacks Equity Research
Philips (PHG) announces its latest innovation, Philips CT 5300, which leverages the power of AI at every stage in CT scanner operation to enhance productivity and diagnostic capabilities.
Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer
by Zacks Equity Research
Profound Medical (PROF) collaborates with Siemens to boost prostate cancer treatment procedures by combining their technologies.
Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact
by Zacks Equity Research
Myriad Genetics' (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential for a pan-cancer investigation.
Veeva Systems (VEEV) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both segments.
Veradigm (MDRX) to Acquire AI Service Provider ScienceIO
by Zacks Equity Research
Veradigm (MDRX) is set to acquire ScienceIO to benefit its Provider, Payer and Life Sciences businesses, offering highly differentiated and advanced products to its customers.
Cooper Companies (COO) Q1 Earnings Top, '24 Outlook Raised
by Zacks Equity Research
Cooper Companies' (COO) first-quarter fiscal 2024 revenues reflect a solid segmental performance with improved adjusted earnings amid rising expenses.
Inari Medical (NARI) Q4 Earnings Improve Y/Y, Gross Margin Down
by Zacks Equity Research
Inari Medical's (NARI) fourth-quarter earnings miss, while sales match estimates. Gross margin improves while the company incurs losses at the operating level.
Merit Medical (MMSI) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the fourth quarter.
Integra's (IART) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Integra's (IART) Q4 revenues are impacted by the decline in the Tissue Technologies segment.
DENTSPLY SIRONA (XRAY) Q4 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q4 revenues improve year over year. Challenging macro headwinds linger.
National Vision (EYE) Q4 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
National Vision's (EYE) Q4 adjusted comparable store sales growth is driven by ongoing strength within America's Best and Eyeglass World sales.
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
by Zacks Equity Research
Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.